A detailed look at the European Medicines Agency's recommendations for use of Janus kinase inhibitors in patients with atopic dermatitis.

Risk of developing adverse events of special interest (eg, cardiovascular events, malignancy) is higher in patients with RA than in patients with AD, because of the higher prevalence of the underlying risk factors CONCLUSIONS: The benefit-risk profile of JAKi approved for AD remains favorable, including use as first-line systemic therapy for patients with AD <65 years of age and without CV or malignancy risk factors.